Evidence map›Paper›PMID 41282540›Full record

ArticleBiochemistry and biophysics reports2025

Involvement of Activin E depletion in metabolic dysfunction-associated steatohepatitis.

Maho Sakaki, Tatsuya Shikata, Kensuke Aoki, Masaaki Takano, Akira Kurisaki, Masayuki Funaba, Osamu Hashimoto

Abstract read
In one paragraph

Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maho SakakiLaboratory of Veterinary Toxicology, College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, 252-0880, Japan.
Tatsuya ShikataFaculty of Veterinary Medicine, Kitasato University, School of Veterinary Medicine, Towada, Aomori, 034-8628, Japan.
Kensuke AokiFaculty of Veterinary Medicine, Kitasato University, School of Veterinary Medicine, Towada, Aomori, 034-8628, Japan.
Masaaki TakanoFaculty of Veterinary Medicine, Kitasato University, School of Veterinary Medicine, Towada, Aomori, 034-8628, Japan.
Akira KurisakiGraduate School of Biological Sciences, Nara Institute of Science and Technology, Ikoma, Nara, 630-0192, Japan.
Masayuki FunabaDivision of Applied Biosciences, Graduate School of Agriculture, Kyoto University, Kitashirakawa Oiwakecho, Kyoto, 606-8502, Japan.
Osamu HashimotoLaboratory of Veterinary Toxicology, College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, 252-0880, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activin E is a liver-derived hepatokine belonging to the transforming growth factor-β superfamily, and it promotes energy expenditure by activating brown and beige adipocytes. Activin E also possesses anti-lipolytic activity. When Activin E knockout (KO) mice are fed a high-fat diet, energy storage in adipose tissue is impaired, leading to ectopic fat accumulation in the liver. In this study, we investigated the involvement of Activin E depletion in metabolic dysfunction-associated steatohepatitis (MASH), and we characterized the phenotype of Activin E-KO mice under a high-fat diet. Despite being protected from obesity, Activin E-KO mice developed pronounced hepatomegaly, hepatic triglyceride accumulation, and histological features consistent with MASH, including steatosis, ballooning degeneration, fibrosis, and increased hepatic crown-like structures. An RNA sequencing analysis showed a gene expression signature characteristic of MASH, including upregulation of inflammatory and fibrogenic pathways. In contrast, white adipose tissue mass and adipocyte size were markedly reduced, accompanied by elevated circulating non-esterified fatty acid and insulin concentrations, indicating adipose tissue dysfunction and insulin resistance. These features were observed even in the absence of obesity, indicating a lean-type MASH phenotype. Notably, Activin E-KO female mice showed delayed disease onset, suggesting estrogen-related protection. Our findings establish Activin E as a key regulator of adipose-liver metabolic communication and suggest that its loss promotes MASH via impaired lipid storage in white adipose tissue and an increased hepatic lipid burden. High-fat diet-fed Activin E-KO mice represent a novel lean-type MASH model and may serve as a useful platform for investigating hepatokine-targeted therapies.

Indexed as

Adipose tissueInhbeInsulin resistanceMASLDObesity

Identifiers

PMID41282540
PMCPMC12634864

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.